Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.790
0.00 (0.00%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Innate Pharma Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Innate Pharma stock have an average target of 6.50, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 263.13% from the current stock price of 1.79.
Analyst Consensus: Buy
* Price targets were last updated on May 14, 2026.
Analyst Ratings
The average analyst rating for Innate Pharma stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $5 | Buy | Reiterates | $5 | +179.33% | May 14, 2026 |
| BTIG | BTIG | Buy Maintains $8 | Buy | Maintains | $8 | +346.93% | May 14, 2026 |
Financial Forecast
Revenue This Year
31.21M
from 9.01M
Increased by 246.64%
Revenue Next Year
64.75M
from 31.21M
Increased by 107.43%
EPS This Year
0.95
EPS Next Year
2.15
from 0.95
Increased by 126.32%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 100.0M | 267.0M | |
| Avg | 31.2M | 64.7M | |
| Low | 4.2M | 6.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1,010.5% | 755.4% | |
| Avg | 246.6% | 107.4% | |
| Low | -53.4% | -79.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | 0.95 | 2.15 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | 126.3% | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.